Cogent Biosciences Shares Face Pullback Following Stellar Rally

Cogent Biosciences US19240Q2012

After an extraordinary surge that saw its value multiply more than fourfold this year, Cogent Biosciences is experiencing a significant market correction. The biotech firm’s stock, which reached an all-time peak of $40.76 in late November, has now declined for three consecutive trading sessions, recently changing hands around $38.98. This downturn prompts investors to question whether the remarkable bull run has concluded.